175 related articles for article (PubMed ID: 32798406)
1. [Effect of Serum Free Light Chain Ratio and Normalization Ratio after Treatment on Diagnosis and Prognosis of Patients with Newly Diagnosed Multiple Myeloma].
Li ZQ; Tian WW; Guo YF; Ma LM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1245-1250. PubMed ID: 32798406
[TBL] [Abstract][Full Text] [Related]
2. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
4. [Value of Serum Free Light Chain Kappa/Lambda Ratio Detection Combined with Immunofixation Electrophoresis in the Prognosis Evaluation of Patients with Multiple Myeloma].
Jiang XN; Chen JF; Wang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):191-195. PubMed ID: 32027275
[TBL] [Abstract][Full Text] [Related]
5. [Effect of Serum Free Light Chain on Renal Function and Prognosis in Patients with Newly Diagnosed Multiple Myeloma].
Chen XD; Luo XF; Zu YP; Ye H; Li LL; Chen QL; Xie WZ; Yang T; Hu JD; Wei LX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1862-1868. PubMed ID: 31839051
[TBL] [Abstract][Full Text] [Related]
6. [Effect of free light chain ratio normalization after treatment on prognosis of patients with multiple myeloma].
Meng QQ; Wang JN; Song M; Bao HY; Hou YQ; Zhang LB; Jiang SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1640-3. PubMed ID: 25543489
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
Tacchetti P; Cavo M; Rocchi S; Pezzi A; Pantani L; Brioli A; Testoni N; Terragna C; Zannetti BA; Mancuso K; Marzocchi G; Borsi E; Martello M; Rizzello I; Zamagni E
Leuk Lymphoma; 2016 Sep; 57(9):2058-64. PubMed ID: 26763357
[TBL] [Abstract][Full Text] [Related]
8. [Clinical Significance of Serum Free Light Chain and Its κ/λ Ratio in Patients with Multiple Myeloma].
Zhao D; Jiang JQ; Lin L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1173-1178. PubMed ID: 31418375
[TBL] [Abstract][Full Text] [Related]
9. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
[TBL] [Abstract][Full Text] [Related]
10. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
[TBL] [Abstract][Full Text] [Related]
11. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
Maltezas D; Dimopoulos MA; Katodritou I; Repousis P; Pouli A; Terpos E; Panayiotidis P; Delimpasi S; Michalis E; Anargyrou K; Gavriatopoulou M; Stefanoudaki A; Tzenou T; Koulieris E; Sachanas S; Dimou M; Vassilakopoulos TP; Angelopoulou MK; Pangalis GA; Kyrtsonis MC
Hematol Oncol; 2013 Jun; 31(2):96-102. PubMed ID: 22961993
[TBL] [Abstract][Full Text] [Related]
12. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
[TBL] [Abstract][Full Text] [Related]
13. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
Yağcı M; Karakaya F; Suyanı E; Haznedar R
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
[TBL] [Abstract][Full Text] [Related]
15. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
[TBL] [Abstract][Full Text] [Related]
16. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios.
Singhal S; Vickrey E; Krishnamurthy J; Singh V; Allen S; Mehta J
Blood; 2009 Jul; 114(1):38-9. PubMed ID: 19411633
[TBL] [Abstract][Full Text] [Related]
17. Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Tacchetti P; Rocchi S; Zamagni E; Barbato S; Rizzello I; De Cicco G; Pantani L; Mancuso K; Fusco A; Dozza L; Ursi M; Favero E; Terragna C; Testoni N; Cavo M
Am J Hematol; 2022 Dec; 97(12):1607-1615. PubMed ID: 36198076
[TBL] [Abstract][Full Text] [Related]
18. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
[No Abstract] [Full Text] [Related]
19. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.
Dytfeld D; Griffith KA; Friedman J; Lebovic D; Harvey C; Kaminski MS; Jakubowiak AJ
Leuk Lymphoma; 2011 Jul; 52(7):1271-80. PubMed ID: 21699382
[TBL] [Abstract][Full Text] [Related]
20. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.
Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hwa YL; Dingli D; Kapoor P; Hayman SR; Lust JA; Kyle RA; Kumar SK
Leukemia; 2015 Oct; 29(10):2033-8. PubMed ID: 25962523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
